OGN — Organon & Co.

Organon (OGN) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Revenue: $6.2 billion for the full year 2025, down 3% year-over-year (YoY) on both reported and constant currency basis.
• Adjusted EBITDA: $1.9 billion for 2025, consistent with 2024.
• Net Loss: $205 million in Q4 2025, translating to a loss of $0.79 per diluted share, compared to a net income of $109 million or $0.42 per diluted share in Q4 2024.
• Non-GAAP Adjusted Net Income: $165 million ($0.63 per diluted share) in Q4 2025, down from $235 million ($0.90 per diluted share) in Q4 2024.
• Free Cash Flow: $960 million for 2025, consistent with the previous year.
• Net Leverage Ratio: Approximately 4.3x at year-end, with expectations to reduce it below 4x by end of 2026.

2. Strategic Updates and Business Highlights:

• Biosimilars: Strong performance driven by Hadlima, which grew 61% YoY. New denosumab biosimilars launched in late 2025.
• Nexplanon: FDA approved an sNDA to extend the duration from 3 to 5 years, potentially broadening the market.
• Cost Management: Achieved over $200 million in cost savings in 2025, maintaining adjusted EBITDA margins flat despite gross margin degradation.
• Divestiture: Sold the Jada system for approximately $390 million, aimed at debt reduction.
• Focus on Women's Health: Continued emphasis on expanding access to Nexplanon and enhancing training programs.

3. Forward Guidance and Outlook:

• 2026 Revenue and EBITDA Guidance: Projecting flat revenue of approximately $6.2 billion and adjusted EBITDA of about $1.9 billion.
• Market Dynamics: Expecting continued pressure on Nexplanon due to policy-related access restrictions and the transition to a 5-year label.
• Cost Management: Anticipating further operating expense reductions and maintaining a disciplined approach to capital deployment.

4. Bad News, Challenges, or Points of Concern:

• Declining Metrics: Revenue from women's health down 16% YoY in Q4; Nexplanon sales decreased 20% in Q4 and 4% for the full year.
• Loss of Exclusivity (LOE): The LOE of Atozet impacted revenue significantly, contributing to a $200 million loss for the year.
• Pricing Pressure: Experienced approximately $180 million in negative pricing impacts for 2025, primarily in respiratory and fertility segments.
• Regulatory Challenges: Ongoing headwinds from government policy changes affecting access to Nexplanon and competitive pressures in the fertility market.

5. Notable Q&A Insights:

• Concerns were raised about the scope of an internal audit related to purchasing practices, with questions about the thoroughness of the investigation.
• Management acknowledged that the recent FDA guidance on biosimilars is seen as incremental rather than transformative.
• Nexplanon’s transition to a 5-year label may lead to a temporary dip in sales due to the loss of reinsertions, with expectations of stabilization in future years.
• The company is committed to managing operating expenses while ensuring investments in growth drivers like Vtama and Nexplanon’s REMS program.

This summary encapsulates the key financial performance, strategic initiatives, outlook, and challenges faced by Organon, providing a comprehensive overview of the company's current standing and future direction.